Clinical characteristics that impact onabotulinumtoxinA treatment adherence in patients with spasticity from ASPIRE

M Fredericks; A Esquenazi; W Feng; GF Wittenberg; P Gallien; Alessio BARICICH; K Fanning; A Zuzek; GE Francisco; DS Bandari

Clinical characteristics that impact onabotulinumtoxinA treatment adherence in patients with spasticity from ASPIRE

M Fredericks
, A Esquenazi
, W Feng
, GF Wittenberg
, P Gallien
, Alessio BARICICH
, K Fanning
, A Zuzek
, GE Francisco
, DS Bandari

Dipartimento di Scienze della Salute

Risultato della ricerca: Contributo alla conferenza › Abstract › peer review

Lingua originale	Inglese
Pagine	52-52
Numero di pagine	1
Stato di pubblicazione	Pubblicato - 2019

Accesso al documento

http://hdl.handle.net/11579/112435

Altri file e collegamenti

handle

Cita questo

@conference{2404dfdb08cb4e4896a1514107bd80fd,

title = "Clinical characteristics that impact onabotulinumtoxinA treatment adherence in patients with spasticity from ASPIRE",

author = "M Fredericks and A Esquenazi and W Feng and GF Wittenberg and P Gallien and Alessio BARICICH and K Fanning and A Zuzek and GE Francisco and DS Bandari",

year = "2019",

language = "English",

pages = "52--52",

}

TY - CONF

T1 - Clinical characteristics that impact onabotulinumtoxinA treatment adherence in patients with spasticity from ASPIRE

AU - Fredericks, M

AU - Esquenazi, A

AU - Feng, W

AU - Wittenberg, GF

AU - Gallien, P

AU - BARICICH, Alessio

AU - Fanning, K

AU - Zuzek, A

AU - Francisco, GE

AU - Bandari, DS

PY - 2019

Y1 - 2019

UR - https://iris.uniupo.it/handle/11579/112435

M3 - Abstract

SP - 52

EP - 52

ER -